Atomoxetine (Strattera) Dosing for a 15-Year-Old Weighing 57.6kg
For a 15-year-old patient weighing 57.6kg, the appropriate dose of atomoxetine (Strattera) is 75mg daily, administered either as a single morning dose or divided into two doses (morning and late afternoon). 1
Initial Dosing
- Since the patient weighs 57.6kg (which is over 40kg), the appropriate dosing follows the "over 40kg" category 1
- Initiate treatment at 40mg total daily dose 1
- After a minimum of 3 days, increase to the target dose of approximately 80mg daily 1
- The dose can be administered either as a single morning dose or divided into two doses (morning and late afternoon/early evening) 1
Maintenance Dosing
- After 2-4 additional weeks, the dose may be increased to a maximum of 100mg if optimal response is not achieved 1
- The maximum recommended total daily dose for adolescents over 40kg is 100mg 1
- Long-term efficacy has been demonstrated in the dose range of 1.2-1.8mg/kg/day for pediatric patients 1
Administration Considerations
- Atomoxetine can be taken with or without food 1
- Capsules should be taken whole and not opened 1
- The medication can be discontinued without tapering 1
Special Considerations
- If the patient is a poor CYP2D6 metabolizer or is taking strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine), start at 40mg/day and only increase to 80mg/day if symptoms don't improve after 4 weeks and the initial dose is well tolerated 1
- Prior to initiating treatment, screen for personal or family history of bipolar disorder, mania, or hypomania 1
Monitoring
- Periodically reevaluate the long-term usefulness of the medication 1
- Monitor for potential side effects including headache, abdominal pain, decreased appetite, nausea, and somnolence 2
- Watch for changes in heart rate and blood pressure, as atomoxetine is generally associated with statistically (but not clinically) significant increases in these parameters 2
- Monitor height and weight, as there may be an initial loss in expected growth that typically returns to normal with longer-term treatment 2